61% expect an
economic recovery
SURVEY SNAPSHOT
Nothing returns to normal without life sciences. Tasked with charting a sustainable road to recovery for both the industry and the global economy at large, life sciences CFOs feel confident about the pivots they made in crisis and are optimistic for growth in 2021.
2021 Life Sciences CFO
Outlook Survey
The Road to Recovery
R&D investment on the rise
Interest in partnerships and collaborations increases
Digital transformation cited as top strategy for growth
Building resiliency into supply chains becomes crucial
Outcomes-based contracts with providers uptick in popularity
Doubling Down on R&D
While investments in non-COVID-19 areas of R&D slowed over the past year, life sciences organizations have shown immense agility in reallocating resources effectively, efficiently and at scale to meet greater pandemic-
driven need.
30%
have already rerouted resources to COVID-related research
in 2021:
plan to increase
R&D spending
69%
plan to invest in
cell therapy
57%
plan to invest in wearables
plan to invest in immunotherapies
56%
While the pandemic’s toll on health and the economy has been massive, it has also fast-tracked opportunities for meaningful collaboration, innovation and expansion throughout the industry.
Opportunities Abound
As COVID-19 continues to highlight vulnerabilities on an international scale, life sciences CFOs are focused on building greater resiliency and agility into their supply chains.
Identifying alternative / backup suppliers
61%
Supplying the Future
Conducting a supply chain risk assessment
57%
Investing in supply chain technology
54%
Bolstering inventory of select drugs or devices
50%
Supply chain shifts
The 2021 BDO Life Sciences CFO Outlook Survey polled 100 CFOs at biopharmaceutical, pharmaceutical, biotech, medical equipment and supplies manufacturing, and physical, engineering and life sciences subsectors with revenues ranging from $250 million to $3 billion in September 2020. The survey was conducted by Rabin Research Company, an independent marketing research firm, using Op4G’s panel of executives.
Methodology
TYPE OF LIFE SCIENCES ORGANIZATION
Survey Respondents
ANNUAL REVENUE
In the last six months, life sciences CFOs say their organizations have experienced:
company type
57%
LEARN MORE
BDO'S TAKE
While the prioritization of COVID-19 R&D is expected to continue until effective products are commercialized, a significant bounce back of R&D investments outside of pandemic-related research is expected in the new year.
BDO'S TAKE
In 2021, a focus on efficient, sustainable and value-based transformation—and financing—will be key. As organizations seek the scale, scope and speed to operate in today’s environment, they must focus on driving digital agility, improving patient outcomes and fostering transparency to prove efficacy to investors and the public.
BDO'S TAKE
To minimize regional and country-specific impacts to sourcing and production processes, life sciences organizations should consider geographical diversification of their supply chains. However, as international operations may be disrupted by ongoing or emerging policy moves at the federal level, CFOs must carefully consider trade and
tariff implications.
Methodology
Survey Respondents
DOWNLOAD THE full REPORT
Thank you! A copy of the report has been sent to your inbox.
Last year, energy CFOs prioritized business continuity and protecting cashflow. But as the industry recovers, long-term plans for the energy transition are coming back into focus.
Outlook for Energy Transition
BDO'S TAKE
Other risks include trade and tariff policy, environmental mandates and the impact of a new regulatory regime. By increasing spending in risk and compliance, energy CFOs will be able to face these challenges. Effective contingency planning, agile supply chains and operational efficiency will also help CFOs adapt more quickly to disruption and seize new opportunities.
The pandemic compounded preexisting headwinds and introduced new challenges for the industry, and the road ahead is uncertain. Energy CFOs are preparing to meet these hurdles and navigate future disruption head on.
An Evolving Threat Landscape
BDO'S TAKE
To keep investor interests high, energy companies must showcase their profitability and potential. To do so, they will need to continue to cut costs, boost operational efficiencies and demonstrate an ability to ensure continuity and manage any future fluctuations in demand.
In 2021, capital access will be vital in determining which companies can execute on their strategic plans. Fortunately, energy CFOs are looking to a variety of sources to secure the cashflow needed to forge ahead.
Reclaiming Capital Access
61% expect economic recovery this year
Most plan to finance new renewables projects this year
Solar is expected to dominate the renawables market
64% believe profitability will increase in 2021
50% of O&G CFOs predict oil will average $60+/ bbl over the next 5 years
Trade and tariffs are CFOs’ top policy concern
SURVEY SNAPSHOT
While COVID-19 and the recession compounded challenges for the industry, middle market energy CFOs are cautiously optimistic about 2021. They’re focused on expanding capital access, adapting to emerging risks and investing in the shift to renewables as they look to refuel for the future.
LEARN MORE
2021 Energy CFO Outlook Survey
Refueling for the Future
Methodology
Survey Respondents
DOWNLOAD THE full REPORT
BDO'S TAKE
Reimagining traditional operations to support renewable energy is a business imperative. Conducting contingency planning, upskilling a workforce for industry shifts and adopting automated processes will enable companies to execute their long-term goals for the energy transition.
The 2021 BDO Energy CFO Outlook Survey polled 100 middle market energy CFOs with revenues ranging from $250 million to $3 billion. The survey was conducted by Rabin Research Company, an independent marketing research firm, in September 2020 using Op4G’s panel of executives.
Methodology
ANNUAL REVENUE
SUBSECTOR
Survey Respondents
Thank you! A copy of the report has been sent to your inbox.
have already rerouted resources to COVID-related research
30%
plan to increase
R&D spending
69%
plan to invest in
cell therapy
57%
plan to invest in wearables
57%
plan to invest in immunotherapies
56%
in 2021:
In the last six months, life sciences CFOs say their organizations have experienced:
Identifying alternative / backup suppliers
61%
Conducting a supply chain risk assessment
57%
Investing in supply chain technology
54%
Bolstering inventory of select drugs or devices
50%
Supply chain shifts
organization type
GET THE FULL REPORT SENT TO YOUR INBOX
GET THE FULL REPORT SENT TO YOUR INBOX
Want more than just the key takeaways? Read the full report.
Download Full Report Now
Email Full Report for Later
Want more than just the key takeaways? Read the full report.
DOWNLOAD FULL REPORT NOW
Email Full Report for Later